Stockreport
Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q2 2018 Results - Earnings Call Transcript [Seeking Alpha]
Last corcept therapeutics earnings: 8/9 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations: corcept.com/investors
PDF
Corcept Therapeutics Incorporated (NASDAQ: CORT ) Q2 2018 Earnings Conference Call August 9, 2018 5:00 PM ET Executives Charles Robb - Chief Financial Officer Joseph Belanoff - President and Chief Executive Officer Robert Fishman - Chief Medical Officer Sean Maduck - Senior Vice President, Commercial Analysts Neil Carnahan - Stifel, Nicolaus & Company Tazeen Ahmad - Bank of America Merrill Lynch Corey Davis - Seaport Global Securities LLC Matthew Kaplan - Ladenburg Thalmann Alan Leong - BioWatch News Operator Good day and welcome to the Corcept Therapeutics Conference Call. Today’s conference is being recorded. [Operator Instructions] At this time, I would like to turn the conference over to Charlie Robb. Please go ahead, sir. Charles Robb Good afternoon. I’m Charlie Robb, Corcept’s Chief Financial Officer. Thank you all for joining us. Earlier today, we issued a press release giving our second quarter financial results, announcing a stock re
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | CORT | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
CORT alerts
CORT alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CORT alerts
High impacting CORCEPT THERAPEUTICS news events
Weekly update
A roundup of the hottest topics
CORT
NEWS
NEWS
- Corcept Therapeutics Incorporated (NASDAQ: CORT) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating.[MarketBeat]
- Corcept Therapeutics Incorporated (NASDAQ: CORT) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating.[MarketBeat]
- Corcept Therapeutics Incorporated (NASDAQ: CORT) was given a new $17.00 price target on by analysts at Cantor Fitzgerald. They now have a "hold" rating on the stock.[MarketBeat]
- Corcept Therapeutics receives Orphan Drug Designation for Relacorilant as treatment for pancreatic cancer [Seeking Alpha][Seeking Alpha]
- Corcept Therapeutics Receives Orphan Designation for Relacorilant as Treatment for Pancreatic Cancer[GlobeNewswire]
- More
CORT
SEC Filings
SEC Filings
- 10/9/18 - Form 4
- 9/11/18 - Form 4
- 8/22/18 - Form 4
- CORT's page on the SEC website
- More